Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.74 |
| ▸ | RAF1 | P04049 | 4/20 | 0.74 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.73 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.65 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18960503 | 0.88 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6469280 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002319 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002182 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL18966417 | 0.81 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002320 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL15606600 | 0.81 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002188 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002183 | 0.81 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DCSNK1EALOX5 | |
| SCHEMBL18960500 | 0.81 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102207-B1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY SCIENCE TECH & RES (SG) | 2022-05-11 | — | — | EP | disclosed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| WO-2015119579-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK13 234/4885MAPK12 366/4885 |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK13 234/4885MAPK12 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.